CEACAM5 Specific Neutra™ Antibody Products
Product listAre you struggling with prolonged timelines in therapeutic antibody development or inconsistent results in targeting CEACAM5? Creative Biolabs' CEACAM5 specific Neutra™ antibody products leverage advanced recombinant engineering and high-throughput epitope mapping to deliver ultra-specific, high-affinity antibodies, enabling robust detection and functional blockade of CEACAM5 in translational research.
Introduction to CEACAM5
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (CEACAM5), also designated CD66e, is a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein belonging to the CEACAM family. Primarily expressed in epithelial tissues, CEACAM5 participates in intercellular adhesion, immune modulation, and intracellular signaling. Its overexpression is tightly linked to malignant transformation, metastasis, and immune evasion across multiple carcinomas.
- Structural Insights into CEACAM5
CEACAM5 features an immunoglobulin (Ig)-like domain organization, comprising multiple extracellular Ig variable-like (IgV) and Ig constant-like (IgC2) domains. Its heavily glycosylated structure promotes homophilic and heterophilic interactions, while the N-terminal domain mediates ligand binding. Structural studies reveal that CEACAM5 dimerization is essential for activating downstream oncogenic signaling.
- CEACAM5-Associated Signaling Pathways
CEACAM5 engages with integrins and growth factor receptors to dysregulate key pathways, including:
- PI3K/AKT/mTOR: Drives cell survival, proliferation, and metabolic reprogramming.
- MAPK/ERK: Enhances metastatic potential via epithelial-mesenchymal transition (EMT).
- Wnt/β-catenin: Facilitates tumor stemness and chemoresistance.
These interactions position CEACAM5 as a central regulator of tumor progression.
Fig.1 Signaling initiated by epithelial CEACAMs, including the CEACAM5.1
- CEACAM5 in Disease Pathogenesis
CEACAM5 is a validated biomarker and therapeutic target in adenocarcinomas, notably colorectal, gastric, and non-small cell lung cancers (NSCLC). Overexpression correlates with advanced tumor stages, poor prognosis, and resistance to conventional therapies. Its role in suppressing T-cell activation further underscores its relevance in cancer immunology.
Applications of CEACAM5 Neutralizing Antibodies
- Precision Cancer Diagnostics
CEACAM5 antibodies enable quantitative detection of tumor-associated CEACAM5 in serum or tissue biopsies via ELISA and IHC. High sensitivity supports early cancer detection and disease stratification in colorectal and pancreatic malignancies.
- Targeted Therapeutic Development
Neutralizing antibodies inhibit CEACAM5-mediated immune evasion, enhancing the efficacy of checkpoint inhibitors. Preclinical models demonstrate reduced tumor burden and metastasis in CEACAM5-positive xenografts when combining anti-CEACAM5 antibodies with anti-PD-1 therapies.
- Monitoring Treatment Response
Longitudinal quantification of CEACAM5 levels using validated antibodies correlates with therapeutic efficacy, guiding adaptive treatment strategies in clinical trials.
- Novel ADC Platforms
Anti-CEACAM5 antibodies serve as targeting moieties for ADCs, delivering cytotoxic payloads directly to tumors while sparing healthy tissues. Phase I trials show promising tumor regression in CEACAM5-high NSCLC patients.
Our Anti-CEACAM5 Neutralizing Antibodies
Creative Biolabs' CEACAM5-specific antibodies are engineered for precision and versatility:
- Mechanism: Block CEACAM5 homodimerization and ligand binding, disrupting pro-tumorigenic signaling.
- Validation: Rigorously tested in flow cytometry, immunohistochemistry (IHC), and surface plasmon resonance (SPR) for specificity (no cross-reactivity with CEACAM1/6/8).
- Formats: Available as conjugates (FITC, HRP, biotin) for in vitro and in vivo applications, including antibody-drug conjugates (ADCs).
These antibodies are indispensable for functional studies, therapeutic development, and biomarker discovery.
Creative Biolabs' CEACAM5 specific Neutra™ antibody products empower researchers to accelerate oncology breakthroughs with industry-leading specificity and reproducibility.
Contact our team today to explore tailored solutions for your CEACAM5-focused projects.
REFERENCE
- Tchoupa, Arnaud Kengmo, Tamara Schuhmacher, and Christof R. Hauck. "Signaling by epithelial members of the CEACAM family–mucosal docking sites for pathogenic bacteria." Cell communication and signaling 12.1 (2014): 27. Distributed under Open Access license CC BY 2.0, without modification. https://doi.org/10.1186/1478-811X-12-27IF
